Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.56 |
| ▸ | PGR | P06401 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28088962 | 1.00 | AR (0.56) | ARPGR | |
| SCHEMBL663706 | 0.84 | AR (0.43) | ARPGR | |
| SCHEMBL30488630 | 0.84 | AR (0.43) | ARPGR | |
| SCHEMBL10284487 | 0.81 | AR (0.73) | AR | |
| SCHEMBL1996075 | 0.78 | AR (0.73) | AR | |
| SCHEMBL221383 | 0.78 | AR (0.62) | ARPGR | |
| SCHEMBL1003776 | 0.78 | AR (0.58) | ARPGR | |
| SCHEMBL1226983 | 0.76 | AR (0.56) | ARPGR | |
| SCHEMBL1128325 | 0.76 | AR (0.74) | ARPGR | |
| SCHEMBL950544 | 0.76 | AR (0.68) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119285594-A | 7-Aminobenzopyrone or 7-aminoquinolinone compound and application thereof | 浙江大学金华研究院 | 2025-01-10 | — | — | CN | disclosed |
| EP-3885340-B1 | ANDROGEN RECEPTOR MODULATING COMPOUNDS | ORION CORP (FI) | 2024-11-27 | — | — | EP | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2023244059-A1 | METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-12-21 | — | — | WO | disclosed |
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| EP-4259634-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-6362372-B2 | HYDROGENATION OF A TRIFLUOROBENZYLNITRILE BY HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA AND A CATALYST COMPRISING A PLATINUM GROUP ELEMENT; EXTREMELY HIGH YIELDS | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| US-20020007086-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6175041-B1 | HYDROGENATING A TRIFLUOROMETHYLBENZONITRILE WITH HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA, USING A RANEY CATALYST | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0154528-B1 | ALKENE, ALKYNE OR CYCLOALKYLENE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-12-11 | — | — | EP | disclosed |
| US-5032592-A | Antiandrogens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-07-16 | — | — | US | disclosed |
| US-4873329-A | ANTIANDROGENS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-10-10 | — | — | US | disclosed |
| EP-0154528-A2 | Alkene, alkyne or cycloalkylene derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | DPP4, DPP3, DPP9 | AR 1911/4885PGR 4589/4885 |
| US-20020007086-A1 | Process for producing trifluoromethylbenzylamines | IDH1, INMT, TH | AR 3622/4885PGR 4454/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | AR 2789/4885PGR 1169/4885 |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | AR 2/4885PGR 252/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | AR 2908/4885PGR 1072/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | AR 893/4885PGR 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.